Fully human monoclonal antibodies take the lead

After the US Food and Drug Administration (FDA) approval in 2002 of the first ever fully human mAb drug adalimumab (Humira^®), fully human mAbs rapidly became the gold standard of mAb-based immunotherapy. Today, 40% of all marketed mAbs are of human origin, and five of the seven mAbs approved in 2017 are fully human mAbs. This shift toward the use of fully human mAbs for immunotherapeutic applications has resulted in a need to rethink antibody discovery and development strategies to optimize the process from beginning to end.

The YUMAB^® platform delivers fully human antibodies closest to natural germline among those on the market, using fast & reliable in vitro discovery technologies. YUMAB’s highly diverse, human antibody libraries contain up to 10e11 natural antibody sequences with specificities to all types of antigens. Unlike animal derived, chimeric, humanized or synthetic antibodies - each YUMAB^® antibody sequence has been shaped in the human body, which maximizes epitope diversity while minimizing immunogenicity and potential adverse effects in clinical development. Our vastly improved technology is also efficient for rare and difficult target antigens and directly optimizes properties such as affinity, stability or interspecies X-reactivity during the early discovery process. First antibody candidates are already identified after only 4–8 weeks and are highly developable into all types of antibody drug formats such as full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides tailored service and partnering concepts to jump-start translation from research to drug development by affordable entry costs, no additional third party obligations, and flexible licensing options.